Press Release: Compass Pathways, Hackensack Meridian ink research deal for psilocybin treatment

Psychedelics-focused biotech Compass Pathways has signed a research collaboration with New Jersey’s Hackensack Meridian Health regarding the delivery model design of its investigational COMP360 psilocybin treatment. In late December, Compass reported phase 2 safety data from the first clinical trial of psilocybin in post-traumatic stress disorder (PTSD). That news came fast on the heels of the Multidisciplinary […]

Go to Source

Powered by WPeMatico